Tumor-associated antigen-lost variant cancer cell

The term "tumor-associated antigen-lost variant cancer cells" refers not to a specific molecule or receptor, but rather to cancer cell populations that have lost the expression of one or more tumor-associated antigens (TAAs). This loss can occur through genetic mutations, deletions, or epigenetic changes affecting genes involved in antigen presentation pathways—most notably components required for MHC class I surface expression such as β2-microglobulin (β2M), TAP, and others. The absence or reduction of these antigens on the tumor cell surface allows these variants to evade immune detection and destruction by cytotoxic T lymphocytes, representing a major mechanism of immune escape in cancer. Such variants are clinically significant because they can lead to resistance against immunotherapies that rely on recognition of TAAs by the immune system. The phrase itself is not a canonical target name but describes a phenotype resulting from selective pressure during immunoediting; therefore, it is not considered an individual therapeutic target and should be flagged as incorrect for structured drug-target databases.